Phase 2 N=118 Disulfiram for Cocaine Abuse
Cocaine Dependence
Primary: Cocaine Use Over Time — 0.01; 0.007; -0.01; 0.007 slope (change in prob of coc-pos utox/d) — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Sickle Cell Anemia · Severe Aplastic Anemia · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Patients With Neutrophil Engraftment — 2 participants
Phase 2 N=205 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16 — 51; 47; 46; 29 participants
Phase 2 N=43 Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
Phase 2 N=109 Stress and Medication Effects on Cocaine Cue Reactivity
Cocaine Related Disorders
Primary: Cocaine Craving — 3.08; 4.36; 1.54; 3.13 units on a scale
Phase 2 N=304 Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
Phase 2 N=73 Rifaximin as a Modulator of Microbial Translocation and Immune Activation
HIV-1 Infection
Primary: Change in CD8+ T-cell Activation From Baseline to Week 4 — 0.00; 0.64 percentage HLA-DR+/CD38+ of CD8+ — p=0.028
Phase 2 N=37 Chantix for Treating Cocaine Dependence
Cocaine Dependence
Primary: Evidence of Abstinence From Cocaine as Indicated by Qualitative Urinalysis for Benzoylecgonine. — 2; 1 participants
Phase 2 N=125 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Average Eye IOP — 26.16; 25.98; 26.26; 23.91 Millimeters of Mercury (mmHg)
Phase 2 N=14 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Neuromyelitis Optica · Devic's Disease
Primary: Median Number of Neuromyelitis Optica (NMO) Attacks Per Year — 3; 0 attacks per year — p=<0.0001
Phase 2 N=47 Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Confirmed Tumor Response — 0 percentage of participants
Phase 2 N=10 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Sarcoma
Primary: Response — 10; 0 participants
Phase 2 N=57 An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
Prostate Neoplasms
Primary: Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter) — 0; 0 Number of Participants
Phase 2 N=46 N-acetylcysteine in Alcohol Dependence
Alcoholism
Primary: Alcohol Consumption (Percentage of Heavy Drinking Days) — 70.2; 58.4; 20.2; 14.7 percentage of heavy drinking days
Phase 2 N=175 Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
Meningococcal Meningitis
Primary: Percentage of Subjects With hSBA Titers ≥1:4 Against Each of 4 Meningococcal Serogroups After MenACWY-CRM Vaccination Administered as 2-Dose or 1-Dose Schedule — 10; 0…